INTRODUCTION OF LYMPHOMA DATABASE OF NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA

Background: Global burden of diseases 2019 showed China had an aggravating lymphoma burden. There was estimated 101,500 new case and 47,000 deaths due to lymphoma. China had 9500 new cases and 2700 deaths of HL, accounting for 10.8% and 9.8% worldwide. China had 92,000 new cases and 44,300 deaths of NHL, accounting for 20.1% and 17.4% worldwide. Moreover, the age-standardized incidence rate of NHL increased by 14.2%, and the age-standardized mortality rate of NHL increased by 21.9%, respectively, over the past three decades. Lymphoma database development: The project of lymphoma database is approved by National Health Commission Capacity Building and Continuing Education Center in November 2021. The general responsible person are Professor Jun Ma and Jun Zhu. The consultant are Professor Zhixiang Shen, Yongping Song and Xiaoqiu Li. The project kickoff meeting was hold in January 2022. The database framework was completed in April 2022. The data input was initialed in May 2022. Representative data: Until March 2023, more than 100 medical centers participated in the project of lymphoma database. There was data of more than 16,000 cases of lymphoma in the database. The data of 100,000 representative cases of lymphoma was chosen and analyzed. The median age was 54 years (range, 3–93 years). Patients aged <18 years accounted for 2.%, 18–60 years accounted for 63.2%, and >60 years accounted for 34.3%. Male accounted for 55.6% and female accounted for 44.4%. The most common nationality was Han (82.9%), followed by Manchu (0.9%), Zhuang (0.9%), Hui (0.8%), Mongolian (0.6%), Yi (0.3%), Miao (0.2%), Bai (0.2%), Tujia (0.1%), and Yao (0.1%). Non-Hodgkin lymphoma accounted for 89% and Hodgkin lymphoma accounted for 11%. Diffuse large B cell lymphoma was the common histological type (44.4%) of B cell lymphoma, followed by follicular lymphoma (11.3%), and marginal zone lymphoma (5.0%). Natural killer/T cell lymphoma was the most common histological type (5.3%) of mature T/NK cell lymphoma, followed by angioimmunoblastic T-cell lymphoma (3.2%), and peripheral T cell lymphoma not otherwise specified (2.6%). In the cohort, 11.7% of patients had stage 1 disease, 21.2% had stage 2 disease, 20.2% had stage 3 disease, and 46.9% had stage 4 disease. Almost one third of patients presented B symptom. According to the Eastern Cancer Cooperation Group performance status score, 50.1% of patients scored 0, 36.8% scored 1, 9.9% scored 2, 2.6% scored 3, and 0.6% scored 4. Keywords: bioinformatics, computational and systems biology, genomics, epigenomics, and other -omics No conflicts of interests pertinent to the abstract.